Licensing In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shire addition of European rights to Dynepo is key driver of $1.6 bil. TKT merger. Roche’s Xenical to be detailed by GSK. Schering-Plough to out-license U.S. rights to Phase III quinolone antibiotic garenoxacin. Kos plans Teveten and Cardizem LA re-launch in June following purchase/licensing pact with Biovail. More licensing deals in brief